Rapid Micro Biosystems Profit Margin

The latest profit margin for RPID is -145.56% as of June 2026. That compares with -145.63% in the prior-year period — up 0.1% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Rapid Micro Biosystems's historical trend and sector peers before judging valuation or financial health.

Over the past year, RPID's profit margin moved from -145.63% to -145.56% — a 0.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rapid Micro Biosystems's valuation or profitability profile.

Against Healthcare companies, RPID currently prints -145.56% for profit margin, while the sector average sits near 21.34%. That is roughly 782.2% below the sector mean. Large gaps often invite a closer look at Rapid Micro Biosystems's growth, margins, and balance sheet.

Profit Margin shows how effectively Rapid Micro Biosystems converts resources into returns. At -145.56%, RPID may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -145.63% in the prior-year period — up 0.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RPID's profit margin (-145.56%), review year-over-year change from -145.63%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.